Moderna Stock Drops After Cancer Vaccine Data Leaks Early

Moderna shares fell as much as 25% on Thursday, October 22, after partial data from its personalized cancer vaccine study with Merck leaked. CNBC and Forbes both reported the 25% figure.

The Wall Street Journal put the drop at nearly 18%. It blamed study details that spread on social media. The paper also reported that the study had been closely guarded before the leak.

Merck's stock moved much less. According to BioSpace, Merck shares fell by just over 1%, to $147.93. Bloomberg described the program as a personalized melanoma vaccine that the two companies were developing together. It reported that investors did not think the leaked data proved the vaccine's value.

The trial behind the leak is called INTerpath-001. It is a Phase 3 study, the largest stage of testing before a company asks regulators to approve a drug. It tested intismeran autogene together with Keytruda (pembrolizumab), a cancer drug already in use, in patients whose melanoma, a serious skin cancer, had been surgically removed.

On August 19, Merck and Moderna said the trial met its primary goals. Those goals were recurrence-free survival (RFS), the time a patient lives without the cancer coming back, and distant metastasis-free survival (DMFS), the time without the cancer spreading to far-off parts of the body. Merck called this the first positive Phase 3 result for an individualized neoantigen therapy, a treatment built around markers unique to a patient's tumor. It also called it the first for an mRNA-based cancer therapy, a technology that uses instructions the body's cells can read.

AJMC reported on October 23 that the personalized vaccine plus standard treatment cut the risk of recurrence by 42%. Keep in mind what that number means. It is a relative reduction in risk, not a direct gain in survival. A headline percentage like this can sound bigger than the real change for patients.

The doctors and the market reacted in opposite ways. Bloomberg reported on October 23 that oncologists, the cancer specialists, praised the leaked melanoma results even as Moderna's shares fell.

In my view, this gap is less a contradiction than a difference in what each group was judging. Doctors weighed the size of the effect against the limited options for melanoma after surgery. Investors were really asking a yes-or-no question about approval and sales. A partial, unofficial release gave them no way to know whether the result would hold up once the full data were reviewed.

The bigger lesson, to my mind, is about how news gets out, not about the drug itself. A leak moves the timing and framing of a trial result from the company to whoever holds the document. Investors then trade on fragments, and those fragments get reread in whatever direction the next post pushes. That helps explain why two sources reporting the same day disagree by seven percentage points on Moderna's drop. Prices for a fast-moving stock depend on when they were measured, and a leak-driven move offers little solid ground for either number. It is a bit like judging a film from a few stills posted online.

For savers and fund holders, the point is narrower than the headlines suggest. Both companies are tied to this program. Merck's move of about 1% suggests the market saw the melanoma result as a small part of a much larger company. Moderna's bigger reaction suggests that more of its value rests on fewer products. Whether the 42% figure turns into real money depends on data that were not in the leak, and on regulatory steps the companies have yet to take.

In my view, the episode also shows how much of a clinical story can move before a company says anything official. The trial results came out in August. The detailed melanoma data surfaced in October. The stock moved before the companies had shared the full picture. For anyone following this name, I would watch the official disclosure, not the first copy of a slide deck.